• A federal jury has asked Eli Lilly And Company (NYSE: LLY) to pay Teva Pharmaceuticals International GmbH $176.5 million after a trial to determine whether its migraine drug Emgality infringed three Teva patents.

• The jury agreed with Teva that Lilly's Emgality violated its rights in the patents, which relate to its migraine drug Ajovy.

• The jury also found that Lilly infringed the patents willfully and rejected its argument that the patents were invalid, Reuters reported.

• A spokesperson for Lilly said the company was disappointed by the verdict but is confident that it will "ultimately prevail" in the case and said the decision does not affect its ability to offer Emgality to patients.

• A Teva spokesperson said the company is pleased with the decision and will "continue to defend its intellectual property rights vigorously."

• Teva sued Lilly over the patents in 2018. The same day Teva sued, the court dismissed two related Teva lawsuits seeking to block Emgality from coming onto the U.S. market.

• Teva also filed a separate, ongoing patent lawsuit against Lilly in Massachusetts over Emgality last year.

• Price Action: LLY shares closed at $362.50 on Wednesday.

• Photo by Okan Caliskan from Pixabay

See more from Benzinga

• Lilly-Boehringer Partnered Jardiance Slows Kidney Disease Progression, Data Shows

• Tesla Shifts China Factory Workers To US Plant, Complete European Approval For AstraZeneca's COVID-19 Shot, Tesla Eyes Cybertruck Commercialization Next Year: Top Stories Tuesday, Nov. 1

• Xi Jinping Reportedly Asks China Army To 'Concentrate All Energy On Fighting A War' Amid Uncertain, Unsta

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.